PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could slow kidney failure in IgA nephropathy patients
Disease control OngoingThis study tests a drug called telitacicept in 318 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants are at high risk of worsening despite standard blood pressure medications. The goal is to see if telitacicept can reduce protein in the u…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for kidney disease: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety of a drug called iptacopan for adults with a kidney disease called primary IgA nephropathy. Participants have already completed earlier studies and will continue taking the drug to monitor side effects and see if it helps slow kidney damag…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC